STIMEP : Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-09-30

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the effectiveness and the safety of deep brain stimulation in drug resistant epilepsy.

This is a double blind, controlled and randomized clinical trial with two cross-over groups and four phases.

Phase 1 : base line, open phase consisting of follow-up of patients with their standard treatment.

Phase 2 : Randomisation, lead implantation, followed by 3 months wash out period with the stimulator switch OFF.

Phase 3 : cross-over, double blind phase : 3 months with stimulator switch ON or OFF depending on randomization allocation, followed by 3 months with the stimulator switch on the opposite position. The placebo consisting of turn OFF the stimulator.

Phase 4 : open phase, one year follow-up of all patients with the stimulator switch ON.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

NCT03283371

Epilepsy, Focal Seizures, Partial Seizures

COMPLETED PHASE2

Study of [11C]DPA-713 for Temporal Lobe Epilepsy

NCT01793532

Epilepsy Temporal Lobe

COMPLETED

A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years

NCT02033902

Epilepsy

COMPLETED

A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

NCT02495844

Highly Drug-resistant Focal Epilepsy

COMPLETED PHASE2

Study of Predictors of Response to Anti Epilepsy in Epilepsy

NCT02883712

Seizure

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The experimental work performed for more than 15 years by several research teams shows in animal models of epilepsy, that several circuits of basal ganglia are involved in the control of epilepsy seizures. The existence of those circuits leads to the possibility of therapeutic applications in particular deep brain stimulation.

Preliminary results (Benabid et al, 2002) (Chabardes et al , 2002) suggest that the neuromodulation of basal ganglia and in particular the subthalamic nucleus and the substantia nigra pars reticulata could have a therapeutic effects in patients with drug resistant epilepsy and no possibility of resection surgery.

This is a double blind, controlled and randomized clinical trial with two cross-over groups and four phases.

Phase 1 : base line, open phase consisting of follow-up of patients with their standard treatment.

Phase 2 : Randomisation, lead implantation, followed by 3 months wash out period with the stimulator switch OFF.

Phase 3 : cross-over, double blind phase : 3 months with stimulator switch ON or OFF depending on randomization allocation, followed by 3 months with the stimulator switch on the opposite position.

Phase 4 : open phase, one year follow-up of all patients with the stimulator switch ON.

There are two differents groups at phase 3 :

* Group A : 10 patients with the stimulator switch ON for three months and switch OFF for the next three months.
* Group B : 10 patients with the opposite sequence, OFF and ON.

Main objective :

\- To show that high frequency deep brain stimulation of the subthalamic nucleus decrease the frequency of epileptic seizure compared with no stimulation.

Secondary objectives :

* To show that high frequency deep brain stimulation of the subthalamic nucleus improve the quality of life.
* To describe the side effects of this device and compare with those described in Parkinson patients. In particular to check the onset of dyskinesia related to dopamine.
* To compare the distribution of seizure frequency after stimulation to the base line.
* To show that the number of patients responding to treatment are higher in the group with stimulator switch ON than in the group with the stimulator turn OFF.
* To compare the number of days without seizure with the stimulator switch ON or OFF.
* To evaluated the neuropsychologic effect induced by the neurostimulation
* To quantify the types and the ratio of different seizures during the ON phase and the OFF phase.
* To monitor the secondary drug use during the study.

Control visits : all patients will have a control visit every 4 weeks during the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy Drug Resistant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

The stimulator is switch ON during the first phase of the cross-over and switch OFF during the second phase

Group Type OTHER

Neurostimulation

Intervention Type DEVICE

High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA

2

The stimulator is switch OFF during the first phase of the cross-over and switch ON during the second phase

Group Type OTHER

Neurostimulation

Intervention Type DEVICE

High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neurostimulation

High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Neurostimulation of subthalamic nucleus

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Epilepsy resistant to antiepileptic drug and dopaminergic D2 agonist.
* No curative exeresis surgery possible
* Metabolism deficiency of DOPA above 1 DS, evaluated by Positron Emission Tomography (PET) using fluorodopa
* Age ranging from 18 to 50
* capacity to consent
* Affiliation to the French Social Security

Exclusion Criteria

* pregnant woman or nursing mother
* change of antiepileptic, 30 days before base line
* convulsive "etat de mal" that requires an hospitalisation, 30 days before base line

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No